Table 3 The table shows the different element and their impact on JCPyV viral load
JC viral load in plasma | P value | JC viral load in urine | P value | |||
|---|---|---|---|---|---|---|
> 4 log10/ml (n = 5) | < 4 log10/ml (n = 15) | > 7 log10/ml (n = 2) | < 7 log10/ml (n = 24) | |||
Age, mean (SD) | 45.60 (10.38) | 48.33 (15.93) | 0.726 | 38.50 (17.67) | 49.79 (15.17) | 0.325 |
Sex | ||||||
Female | 3 (60.0%) | 5 (33.3%) | 0.292 | 1 (50.0%) | 5 (20.8%) | 0.347 |
Male | 2 (40.0%) | 10 (66.7%) | 1 (50.0%) | 19 (79.2%) | ||
Immunosuppression regimen | ||||||
Sirolimus | 5 (100.0%) | 15 (100.0%) | 0 (0.0%) | 1 (4.2%) | 0.768 | |
Mycophenolate Mofetil | 3 (60.0%) | 9 (60.0%) | 1.000 | 1 (50.0%) | 17 (70.8%) | 0.540 |
Cyclosporine | 1 (20.0%) | 6 (40.0%) | 0.417 | 1 (50.0%) | 11 (45.8%) | 0.910 |
Tacrolimus | 2 (40.0%) | 2 (13.3%) | 0.197 | 1 (50.0%) | 1 (4.3%) | 0.019 |
Mycophenolic acid | 1 (6.7%) | 1 (20.0%) | 0.389 | 0 (0.0%) | 3 (12.5%) | 0.595 |
Azathioprine | 5 (100.0%) | 15 (100.0%) | 2 (100.0%) | 24 (100.0%) | ||
Prednisolone acetate | 5 (100.0%) | 15 (100.0%) | 2 (100.0%) | 24 (100.0%) | ||
CR, mean (SD) | 3.32 (4.86) | 1.39 (0.851) | 0.424 | 1.05 (0.21) | 1.48 (0.16) | 0.67 |
GFR, mean (SD) | 78 (23.88) | 69.40 (27.39) | 0.540 | 73 (1.41) | 67.78 (26.3) | 0.359 |
Duration post-transplantation | 8.80 (8.98) | 7.66 (4.80) | 0.002 | 7.5 (2.12) | 7.45 (4.35) | 0.990 |
Diseases | ||||||
Diabetes | 0 (0.0%) | 4 (26.7%) | 0.197 | 0 (0.0%) | 3 (12.5%) | 0.595 |
High blood pressure | 0 (0.0%) | 1 (6.7%) | 0.554 | 0 (0.0%) | 5 (20.8%) | 0.473 |
Glomerulonephritis | 5 (100.0%) | 15 (100.0%) | 0 (0.0%) | 2 (8.3%) | 0.671 | |
Alport syndrome | 5 (100.0%) | 15 (100.0%) | 0 (0.0%) | 2 (8.3%) | 0.671 | |
Nephrotic syndrome | 0 (0.0%) | 1 (6.7%) | 0.554 | 1 (50.0%) | 1 (4.2%) | 0.019 |
Renal stone | 0 (0.0%) | 2 (13.3%) | 0.389 | 0 (0.0%) | 1 (4.2%) | 0.768 |
Polycystic renal | 5 (100.0%) | 15 (100.0%) | 0 (0.0%) | 2 (8.3%) | 0.671 | |
Urinary reflux | 0 (0.0%) | 1 (6.7%) | 0.554 | 1 (50.0%) | 1 (4.2%) | 0.019 |